Synergy in Action

15th Annual Scientific Meeting Posters

Poster PDFs and abstracts are in alphabetical order by author.

Alphs-Clinical trial design considerations for novel therapies in patients showing inadequate response (Abstract)

Anderson-Trials, errors, and placebo prediction: Tradeoffs between effect size and sample size in machine learning models to mitigate the placebo response (Abstract)

Atkins-Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning (Abstract)

Chung-Experimental pain evaluation in Japanese healthy volunteers using the cold pressor test (Abstract)

Cohen-Taming the placebo effect in depression clinical trials: The methodological implementation of a placebo-control reminder script (Abstract)

Correll-The New York assessment of adverse cognitive effects of neuropsychiatric treatment (NY-AACENT): Initial validation findings (Abstract)

Curtin-Implementation of a fully virtual trial in an interventional study of the effects of caffeine on cognition and mood (Abstract)

Daniel-Comparison of PANSS logical error rates using eCOA vs. paper data collection (Abstract)

Farmer-Missed opportunity: Efficient use of baseline can increase power and reduce bias in psychiatric crossover trials (Abstract)

Fua-Outlier safety data with esketamine nasal spray plus an oral antidepressant in treatment-resistant depression (SUSTAIN-2 study) (Abstract)

Gill-A machine learning approach to predict change in diagnostic category in pre-dementia (Abstract)

Kadriu-The kynurenine pathway and bipolar disorder: The intersection of the monoaminergic and glutamatergic systems and immune response (Abstract)

Kalaria-Quantitative disease-drug-trial models for evidence of effectiveness – a case study of negative adolescent schizophrenia trials (Abstract)

Kemethofer-Activity monitoring in patients with Alzheimer’s disease (AD) and irregular sleep-wake-rhythm disorder (ISWRD): How many days are needed for reliable measures? (Abstract)

Khan-Assessing the eCOA user experience (UX) for evaluating virtual functional outcomes (Abstract)

Kott-Exploring the association of PANSS rater change with extreme within-subject variability in schizophrenia clinical trials (Abstract)

Lindenmayer-Procedural and methodological issues in implementing digital health programs in patients with schizophrenia (Abstract)

McNamara-Risks to signal detection in clinical trials: The relationships between operational and clinical risk in an ongoing phase 3 trial in schizophrenia (Abstract)

Nash-How we are measuring up: Comparisons of symptom severity assessments performed by independent vs. site-based raters in a clinical trial for major depressive disorder (Abstract)

Niciu-The neurophysiological effects of intravenous alcohol as potential biomarkers of ketamine’s rapid antidepressant effects (Abstract)

Olugemo-Impact of innovative trial designs on CNS drug development (Abstract)

Ruthirakuhan-Investigating placebo-effects in a randomized controlled trial in patients with moderate-to-severe Alzheimer’s disease and agitation (Abstract)

Shiovitz-Subject to change: Subject variability from early phase 2 to late phase 3 clinical trials (Abstract)

Shoulson-Verbatim reports of problems from >10,000 Parkinson disease patients: Informing natural history and clinical outcome assessments (Abstract)

Wilkinson-Impact of midazolam v. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant (Abstract)

Williamson-Linking adverse events of dissociation reported with esketamine dosing by clinician-perceived severity and CADSS descriptors (Abstract)

Yoshihara-The CSF sampling by lumbar puncture in healthy Japanese elderly Subjects; Age and cultural-specific considerations (Abstract)

Zaragoza-Domingo-Towards more efficient methods for clinical outcome assessment (COA) instrument selection in Alzheimer’s disease (AD) clinical trials (Abstract) 

Ziemann-Identification of neurorestorative biomarkers in patients with relapsing forms of multiple sclerosis (Abstract)